Table 2 |
|||||
|
Growth curves in glioma cells exposed to vehicle or ketone bodies |
|||||
|
21% O2 |
3OHB |
AcAc |
LiCl |
3OHB + AcAc |
3OHB + LiCl |
|
|
|||||
|
U87MG |
94.9 ± 9.9 |
109.7 ± 10.3 |
104.5 ± 11.7 |
107.3 ± 10.1 |
100.8 ± 10.0 |
|
U251MG |
100.2 ± 5.8 |
97.4 ± 5.5 |
97.0 ± 6.9 |
96.1 ± 5.4 |
90.2 ± 5.0 |
|
LNT-229 |
98.4 ± 4.7 |
100.6 ± 3.7 |
109.5 ± 7.9 |
104.0 ± 3.6 |
95.7 ± 4.0 |
|
T98G |
96.3 ± 4.8 |
87.6 ± 4.0 |
91.2 ± 7.8 |
86.1 ± 5.3 |
88.0 ± 4.1 |
|
A172 |
97.1 ± 6.0 |
100.3 ± 5.7 |
99.9 ± 7.4 |
84.9 ± 10.7 |
90.7 ± 5.6 |
|
LNT-229 scrambled sh |
99.9 ± 9.5 |
109.2 ± 6.0 |
103.7 ± 5.3 |
102.2 ± 6.2 |
97.5 ± 6.8 |
|
LNT-229 p53sh |
98.3 ± 5.3 |
102.3 ± 3.2 |
96.5 ± 2.4 |
95.1 ± 2.4 |
95.0 ± 2.8 |
|
|
|||||
|
0.1% O2 |
3OHB |
AcAc |
LiCl |
3OHB + AcAc |
3OHB + LiCl |
|
|
|||||
|
U87MG |
97.7 ± 4.9 |
115.8 ± 5.8 |
115.2 ± 4.9 |
108.8 ± 4.2 |
104.0 ± 5.7 |
|
U251MG |
96.6 ± 2.7 |
102.6 ± 5.0 |
98.1 ± 2.5 |
92.1 ± 5.4 |
86.9 ± 3.0 |
|
LNT-229 |
93.6 ± 3.5 |
103.2 ± 4.9 |
104.4 ± 3.3 |
97.0 ± 3.3 |
91.0 ± 5.1 |
|
T98G |
98.8 ± 10.1 |
100.2 ± 9.1 |
97.3 ± 8.7 |
101.7 ± 7.3 |
91.5 ± 9.9 |
|
A172 |
107.9 ± 15.6 |
93.2 ± 9.2 |
95.8 ± 7.4 |
101.0 ± 8.7 |
91.6 ± 6.8 |
|
LNT-229 scrambled sh |
99.6 ± 5.4 |
104.5 ± 4.7 |
105.4 ± 6.0 |
98.9 ± 4.6 |
103.9 ± 8.2 |
|
LNT-229 p53sh |
94.8 ± 2.5 |
107.4 ± 4.2 |
107.6 ± 5.4 |
102.9 ± 4.0 |
96.0 ± 4.5 |
|
|
|||||
|
Cells were exposed to 3-hydroxybutyrate (3OHB, 5 mM), acetoacetate (AcAc, 5 mM), lithium chloride (LiCl, 5 mM) or both for 36 h at 21% or 0.1% O2 and subsequently stained with crystal violet. Data are expressed as percentages (mean and standard deviation) relative to untreated control cells. |
|||||
|
Maurer et al. BMC Cancer 2011 11:315 doi:10.1186/1471-2407-11-315 |
|||||
